ログイン

Antiparkinsonism drugs

Antiparkinsonism drugs
75問 • 1年前
  • Quinn Karylle Fuentes
  • 通報

    問題一覧

  • 1

    Parkinsonism also know as

    Idiopathic Parkinsonism, Primary Parkinsonism, Paralysis Agitans

  • 2

    Critical brain region (part of basal ganglia) for the production of dopamine and has a critical role in modulating motor movement and reward functions as part of the basal ganglia circuitry.

    Substantia Nigra

  • 3

    Slowly progressive degenerative neurological disorder, characterized tremors, muscular rigidity, bradykinesia, and postural and gait abnormalities

    Parkinsonism.

  • 4

    an eosinophilic rounded inclusion which is made up of alpha-synuclein is present in the affected substantia nigra. It appears in dopaminergic neurons before it dies. Aside from PD, it can also be found in other disease like DEMENTIA.

    Lewy body

  • 5

    Sometimes it may have Genetic Predisposition. Mutation in?

    PINK1, Parkin, alpha synuclein genes

  • 6

    its toxicity mainly by promoting the formation of reactive free radicals in the mitochondria of dopaminergic neurons in the substantia nigra. Results to destruction of dopaminergic neurons leading to Parkinson’s disease

    MPP+ exhibits.

  • 7

    Because of inc Ach, most evident at rest and with low-frequency movement.

    Tremor at rest

  • 8

    Muscle stiffness. It can affect any limb, but it's most common in the arms. It can affect one or both arms.

    Muscle rigidity.

  • 9

    Difficulty in initiating movement

    Akinesia

  • 10

    Slowness in performing common voluntary movements

    Bradykinesia

  • 11

    Decrease body movement

    Hypokinesia

  • 12

    Patient walk with a stopped, flexed posture

    Gait & Postural difficulties

  • 13

    The cause is unknown while treatment may be palliative an the disease is incurable. Most patients suffer from this type of parkinsonism

    Primary parkinsonism

  • 14

    ⏤Minimal to no dopamine deficiency ⏤Mild to no improvement to dopaminergic drugs

    Atypical Parkinsonsim

  • 15

    Type of Parkinson’s with a known cause: Disease, Poisoning, Infections or Drug intake

    Secondary parkinsonism

  • 16

    Inhibit the uptake of dopamine in the vesicle. Increasing it’s degradation.

    Reserpine

  • 17

    A rating tool used to gauge the the severity and progression of Parkinson's disease in patients It is used to evaluate the clinical efficacy of antiparkinson’s drugs and to monitor disease progression.

    Unified parkinson's disease scale.

  • 18

    evaluation of mentation, behavior & mood

    Part 1

  • 19

    Unilateral involvement (half of the body) includes major features of tremor, rigidity or bradykinesia, minimal functional impairment

    Stage 1

  • 20

    Bilateral involvement (entire body) Same clinical manifestation to stage 1. Patient don’t have postural abnormalities

    Stage 2

  • 21

    a self-reported evaluation of the activities of daily living (ADL)

    Part 2

  • 22

    is a clinician-scored motor evaluation

    Part 3

  • 23

    the Hoehn and Yahr staging of severity of Parkinson’s disease

    Part 4

  • 24

    The Schwab and England ADL scale.

    Part 5

  • 25

    Mild to moderate bilateral disease Mild postural imbalance, but still able to function independently

    Stage 3

  • 26

    Bilateral involvement with postural abnormalities Patient requires substantial assistance

    Stage 4

  • 27

    Severe disease Patient is restricted to bed or wheelchair unless aided.

    Stage 5

  • 28

    Dopamine precursor

    Levodopa

  • 29

    Drug of choice for Parkinsonism (not always used) ⏤ Most effective drug however prolonged use decreases its efficacy and increase adverse effects

    Levodopa

  • 30

    L-dopa is converted to Dopamine by dopa decarboxylase thereby increasing the CNS levels of Dopamine in the brain. (T/F)

    True

  • 31

    inhibit metabolism of L-dopa in the periphery thereby increase level of DA in the CNS

    Carbidopa

  • 32

    DRUG HOLIDAYS discontinuance of the drug for 3–21 days temporarily improve responsivenes

    Levodopa

  • 33

    more dopa is available for entry into the brain - Reduce the daily requirements of levodopa by approximately 75%

    Carbidopa

  • 34

    What are drugs that may May increase efficacy of levodopa

    Amantadine, benztropine, procyclidine, trihexyphenidyl

  • 35

    increase peripheral breakdown of L-dopa

    Vitamin B6 pyridoxine

  • 36

    What are the ergot derivatives

    Bromocriptine (Parlodel, Provasyn), Pergolide (Permax)

  • 37

    NON ERGOT DERIVATIVES

    Apomorphine (Apokyn), Ropinirole (Requip), Pramipexole (Sifrol)

  • 38

    Dopamine 2 agonist

    BROMOCRIPTINE, ROTIGOTINE, ROPINIROLE

  • 39

    Stimulates both D1 and D2 receptors

    PERGOLIDE

  • 40

    preferential affinity for the D3 receptors

    PRAMIPEXOLE

  • 41

    Also used in hyperprolactinemia but may increase risk of pulmonary fibrosis

    Bromocriptine (Parlodel)

  • 42

    More effective than bromocriptine Also not used because it is associated with VHD (Valvular heart disease)

    Pergolide (Permax)

  • 43

    Reduces symptoms of parkinsonism- smooths out fluctuations in levodopa response effective in on-off phenomenon

    Pramipexole (Sifrol)

  • 44

    Monotherapy in px with mild dse and as a means of smoothing the response to L-dopa

    Monotherapy in px with mild dse and as a means of smoothing the response to L-dopa

  • 45

    An opioid derivative

    Apomorphine (Apokyn)

  • 46

    First dose phenomenon

    Bromocriptine

  • 47

    Cardiac valvulopathy

    Pergolide

  • 48

    Inhibitors of Dopamine Metabolism

    Mao inhibitors, COMT inhibitors

  • 49

    More potent (5x) than selegiline in preventing MPTP induced parkinsonism

    Rasagiline

  • 50

    Retards the breakdown of dopamine Enhances and prolongs the antiparkinson’s effect of levodopa

    Selegiline

  • 51

    Hepatic necrosis is associated with

    Tolcapone

  • 52

    Rapid withdrawal causes hyperpyrexia and confusion

    Entacapone

  • 53

    Prolong the action of levodopa by diminishing its peripheral metabolism Improves duration of “on-time” and dec “off-time”

    Entacapone, Tolcapone

  • 54

    Dopamine Releaser

    Amantadine symmetrel

  • 55

    It has been reported to antagonize the effects of adenosine at adenosine A2A receptors, which are receptors that may inhibit D2 receptor function.

    Amantadine (Symmetrel)

  • 56

    A violaceous mottling of the skin with a "fishnet" reticular appearance.

    Livedo reticularis

  • 57

    Blocks the excitatory neurotransmitter cholinergic influence in the basal ganglia

    Anti muscarinic

  • 58

    What drug is used in Tremor & Rigidity Management

    Anti muscarinic

  • 59

    Normal phenomenon, enhanced amplitude by anxiety, fatigue, thyrotoxicosis, IV Epinephrine

    PHYSIOLOGIC POSTURAL TREMOR

  • 60

    A postural tremor, sometimes familial

    Essential tremor

  • 61

    Present during movement

    Intentional tremor

  • 62

    Due to parkinsonism

    Rest tremor

  • 63

    Consist of rhythmic oscillatory movements around a join

    Tremor

  • 64

    What are the drug odf choice in movement disorder

    B-blockers, Metoprolol, Antiepileptic

  • 65

    Inherited disorder characterized by progressive chorea and dementia that begins at adulthood ⏤Related to imbalance of Dopamine, Ach, GABA, and perhaps other neurotransmitter in the basal ganglia

    Huntington’s Disease

  • 66

    What isnthe drug of choice in Huntington’s Disease

    Tetrabenazine, Reserpine

  • 67

    a condition of the nervous system. TS causes people to have “tics”.

    Tourette Syndrome (TS)

  • 68

    What is the drug of choice in Tourette Syndrome (TS)

    Haloperidol, Pimozide

  • 69

    ⏤Uncontrollable urge to move the legs, usually because of an uncomfortable sensation.

    Restless legs Syndrome

  • 70

    Restless legs syndrome what is the drug of choice

    Dopaminergic, Ropinirole, Opioid analgesics and BZD

  • 71

    Inherited disorder of copper metabolism results in deposition of copper salts in the liver and other tissues

    Wilson’s Disease

  • 72

    Wilson’s Disease in brain

    Uncontrollable movement

  • 73

    Wilson’s Disease in eye

    Kayser-Fleischer rings)

  • 74

    Wilson’s Disease in liver

    Jaundice

  • 75

    Drug of choice in Wilson’s Disease

    Chelating agent, Penicillamine

  • Cell structure.

    Cell structure.

    Quinn Karylle Fuentes · 28問 · 2年前

    Cell structure.

    Cell structure.

    28問 • 2年前
    Quinn Karylle Fuentes

    Electrolytes and non electrolytes

    Electrolytes and non electrolytes

    Quinn Karylle Fuentes · 29問 · 2年前

    Electrolytes and non electrolytes

    Electrolytes and non electrolytes

    29問 • 2年前
    Quinn Karylle Fuentes

    MW

    MW

    Quinn Karylle Fuentes · 45問 · 2年前

    MW

    MW

    45問 • 2年前
    Quinn Karylle Fuentes

    POST LAB (EXP 4)

    POST LAB (EXP 4)

    Quinn Karylle Fuentes · 38問 · 2年前

    POST LAB (EXP 4)

    POST LAB (EXP 4)

    38問 • 2年前
    Quinn Karylle Fuentes

    Density and specific gravity

    Density and specific gravity

    Quinn Karylle Fuentes · 34問 · 2年前

    Density and specific gravity

    Density and specific gravity

    34問 • 2年前
    Quinn Karylle Fuentes

    FORCES OF ATTRACTION

    FORCES OF ATTRACTION

    Quinn Karylle Fuentes · 18問 · 2年前

    FORCES OF ATTRACTION

    FORCES OF ATTRACTION

    18問 • 2年前
    Quinn Karylle Fuentes

    Microbial growth

    Microbial growth

    Quinn Karylle Fuentes · 63問 · 2年前

    Microbial growth

    Microbial growth

    63問 • 2年前
    Quinn Karylle Fuentes

    Introduction.

    Introduction.

    Quinn Karylle Fuentes · 61問 · 2年前

    Introduction.

    Introduction.

    61問 • 2年前
    Quinn Karylle Fuentes

    Microbial control.

    Microbial control.

    Quinn Karylle Fuentes · 97問 · 2年前

    Microbial control.

    Microbial control.

    97問 • 2年前
    Quinn Karylle Fuentes

    States of matter

    States of matter

    Quinn Karylle Fuentes · 100問 · 2年前

    States of matter

    States of matter

    100問 • 2年前
    Quinn Karylle Fuentes

    Introduction.

    Introduction.

    Quinn Karylle Fuentes · 86問 · 2年前

    Introduction.

    Introduction.

    86問 • 2年前
    Quinn Karylle Fuentes

    Drug development.

    Drug development.

    Quinn Karylle Fuentes · 77問 · 2年前

    Drug development.

    Drug development.

    77問 • 2年前
    Quinn Karylle Fuentes

    CGMP

    CGMP

    Quinn Karylle Fuentes · 9問 · 2年前

    CGMP

    CGMP

    9問 • 2年前
    Quinn Karylle Fuentes

    Pharmaceutical ingredients.

    Pharmaceutical ingredients.

    Quinn Karylle Fuentes · 24問 · 2年前

    Pharmaceutical ingredients.

    Pharmaceutical ingredients.

    24問 • 2年前
    Quinn Karylle Fuentes

    Powdered & granules

    Powdered & granules

    Quinn Karylle Fuentes · 43問 · 2年前

    Powdered & granules

    Powdered & granules

    43問 • 2年前
    Quinn Karylle Fuentes

    Capsule.

    Capsule.

    Quinn Karylle Fuentes · 24問 · 2年前

    Capsule.

    Capsule.

    24問 • 2年前
    Quinn Karylle Fuentes

    Tablets.

    Tablets.

    Quinn Karylle Fuentes · 23問 · 2年前

    Tablets.

    Tablets.

    23問 • 2年前
    Quinn Karylle Fuentes

    Calculatiom of dose

    Calculatiom of dose

    Quinn Karylle Fuentes · 3回閲覧 · 66問 · 2年前

    Calculatiom of dose

    Calculatiom of dose

    3回閲覧 • 66問 • 2年前
    Quinn Karylle Fuentes

    Postlab 5&6

    Postlab 5&6

    Quinn Karylle Fuentes · 29問 · 2年前

    Postlab 5&6

    Postlab 5&6

    29問 • 2年前
    Quinn Karylle Fuentes

    COLLIGATIVE PROPERTIES.

    COLLIGATIVE PROPERTIES.

    Quinn Karylle Fuentes · 33問 · 2年前

    COLLIGATIVE PROPERTIES.

    COLLIGATIVE PROPERTIES.

    33問 • 2年前
    Quinn Karylle Fuentes

    SEMI SOLID

    SEMI SOLID

    Quinn Karylle Fuentes · 69問 · 2年前

    SEMI SOLID

    SEMI SOLID

    69問 • 2年前
    Quinn Karylle Fuentes

    Basic immunology

    Basic immunology

    Quinn Karylle Fuentes · 60問 · 2年前

    Basic immunology

    Basic immunology

    60問 • 2年前
    Quinn Karylle Fuentes

    Basic immunology (2)

    Basic immunology (2)

    Quinn Karylle Fuentes · 62問 · 2年前

    Basic immunology (2)

    Basic immunology (2)

    62問 • 2年前
    Quinn Karylle Fuentes

    Transdermal

    Transdermal

    Quinn Karylle Fuentes · 44問 · 2年前

    Transdermal

    Transdermal

    44問 • 2年前
    Quinn Karylle Fuentes

    Distribution.

    Distribution.

    Quinn Karylle Fuentes · 43問 · 2年前

    Distribution.

    Distribution.

    43問 • 2年前
    Quinn Karylle Fuentes

    Infectious disease.

    Infectious disease.

    Quinn Karylle Fuentes · 65問 · 2年前

    Infectious disease.

    Infectious disease.

    65問 • 2年前
    Quinn Karylle Fuentes

    Infectious diseases (2)

    Infectious diseases (2)

    Quinn Karylle Fuentes · 79問 · 2年前

    Infectious diseases (2)

    Infectious diseases (2)

    79問 • 2年前
    Quinn Karylle Fuentes

    Gram positive ( Bacteriology)

    Gram positive ( Bacteriology)

    Quinn Karylle Fuentes · 35問 · 2年前

    Gram positive ( Bacteriology)

    Gram positive ( Bacteriology)

    35問 • 2年前
    Quinn Karylle Fuentes

    All topic. ( Compressed.)

    All topic. ( Compressed.)

    Quinn Karylle Fuentes · 35問 · 2年前

    All topic. ( Compressed.)

    All topic. ( Compressed.)

    35問 • 2年前
    Quinn Karylle Fuentes

    All topic ( Compressed)

    All topic ( Compressed)

    Quinn Karylle Fuentes · 30問 · 2年前

    All topic ( Compressed)

    All topic ( Compressed)

    30問 • 2年前
    Quinn Karylle Fuentes

    All topics (compressed)

    All topics (compressed)

    Quinn Karylle Fuentes · 13問 · 2年前

    All topics (compressed)

    All topics (compressed)

    13問 • 2年前
    Quinn Karylle Fuentes

    Exercise 6 ; Isotonic solution.

    Exercise 6 ; Isotonic solution.

    Quinn Karylle Fuentes · 28問 · 2年前

    Exercise 6 ; Isotonic solution.

    Exercise 6 ; Isotonic solution.

    28問 • 2年前
    Quinn Karylle Fuentes

    Exercise 5 : Buffers.

    Exercise 5 : Buffers.

    Quinn Karylle Fuentes · 16問 · 2年前

    Exercise 5 : Buffers.

    Exercise 5 : Buffers.

    16問 • 2年前
    Quinn Karylle Fuentes

    Exercise 7 : Factors affecting solubility.

    Exercise 7 : Factors affecting solubility.

    Quinn Karylle Fuentes · 26問 · 2年前

    Exercise 7 : Factors affecting solubility.

    Exercise 7 : Factors affecting solubility.

    26問 • 2年前
    Quinn Karylle Fuentes

    Experiment 8: Disintegration.

    Experiment 8: Disintegration.

    Quinn Karylle Fuentes · 23問 · 2年前

    Experiment 8: Disintegration.

    Experiment 8: Disintegration.

    23問 • 2年前
    Quinn Karylle Fuentes

    Experiment 9 ; Interfacial phenomenon and surface tension.

    Experiment 9 ; Interfacial phenomenon and surface tension.

    Quinn Karylle Fuentes · 35問 · 2年前

    Experiment 9 ; Interfacial phenomenon and surface tension.

    Experiment 9 ; Interfacial phenomenon and surface tension.

    35問 • 2年前
    Quinn Karylle Fuentes

    EXP 9 : Aromatic ammonia spirit.

    EXP 9 : Aromatic ammonia spirit.

    Quinn Karylle Fuentes · 34問 · 2年前

    EXP 9 : Aromatic ammonia spirit.

    EXP 9 : Aromatic ammonia spirit.

    34問 • 2年前
    Quinn Karylle Fuentes

    EXP 10-11 : CAMPHOR WATER AND CINNAMON WATER.

    EXP 10-11 : CAMPHOR WATER AND CINNAMON WATER.

    Quinn Karylle Fuentes · 34問 · 2年前

    EXP 10-11 : CAMPHOR WATER AND CINNAMON WATER.

    EXP 10-11 : CAMPHOR WATER AND CINNAMON WATER.

    34問 • 2年前
    Quinn Karylle Fuentes

    EXP 12: ACACIA MUCILAGE

    EXP 12: ACACIA MUCILAGE

    Quinn Karylle Fuentes · 20問 · 2年前

    EXP 12: ACACIA MUCILAGE

    EXP 12: ACACIA MUCILAGE

    20問 • 2年前
    Quinn Karylle Fuentes

    EXP13&14 : Starch and Barrium sulfate.

    EXP13&14 : Starch and Barrium sulfate.

    Quinn Karylle Fuentes · 33問 · 2年前

    EXP13&14 : Starch and Barrium sulfate.

    EXP13&14 : Starch and Barrium sulfate.

    33問 • 2年前
    Quinn Karylle Fuentes

    EXP 15 : Liquid petroleum emulsion 1.0

    EXP 15 : Liquid petroleum emulsion 1.0

    Quinn Karylle Fuentes · 37問 · 2年前

    EXP 15 : Liquid petroleum emulsion 1.0

    EXP 15 : Liquid petroleum emulsion 1.0

    37問 • 2年前
    Quinn Karylle Fuentes

    EXP 15: Liquid petroleum emulsion 1.1

    EXP 15: Liquid petroleum emulsion 1.1

    Quinn Karylle Fuentes · 23問 · 2年前

    EXP 15: Liquid petroleum emulsion 1.1

    EXP 15: Liquid petroleum emulsion 1.1

    23問 • 2年前
    Quinn Karylle Fuentes

    Enterobacteriaceae

    Enterobacteriaceae

    Quinn Karylle Fuentes · 35問 · 2年前

    Enterobacteriaceae

    Enterobacteriaceae

    35問 • 2年前
    Quinn Karylle Fuentes

    Enterobacteriaceae.

    Enterobacteriaceae.

    Quinn Karylle Fuentes · 28問 · 2年前

    Enterobacteriaceae.

    Enterobacteriaceae.

    28問 • 2年前
    Quinn Karylle Fuentes

    LIQUID DOSAGE FORM 1.0

    LIQUID DOSAGE FORM 1.0

    Quinn Karylle Fuentes · 31問 · 2年前

    LIQUID DOSAGE FORM 1.0

    LIQUID DOSAGE FORM 1.0

    31問 • 2年前
    Quinn Karylle Fuentes

    Liquid dosage form

    Liquid dosage form

    Quinn Karylle Fuentes · 12問 · 2年前

    Liquid dosage form

    Liquid dosage form

    12問 • 2年前
    Quinn Karylle Fuentes

    MICROMERITICS 1.0

    MICROMERITICS 1.0

    Quinn Karylle Fuentes · 44問 · 2年前

    MICROMERITICS 1.0

    MICROMERITICS 1.0

    44問 • 2年前
    Quinn Karylle Fuentes

    EXP 7 : ENDOGENOUS AND EXOGENOUS MICROORGANISMS

    EXP 7 : ENDOGENOUS AND EXOGENOUS MICROORGANISMS

    Quinn Karylle Fuentes · 22問 · 2年前

    EXP 7 : ENDOGENOUS AND EXOGENOUS MICROORGANISMS

    EXP 7 : ENDOGENOUS AND EXOGENOUS MICROORGANISMS

    22問 • 2年前
    Quinn Karylle Fuentes

    EXP 8 : KIRBY-BAUER TECHNIQUE

    EXP 8 : KIRBY-BAUER TECHNIQUE

    Quinn Karylle Fuentes · 40問 · 2年前

    EXP 8 : KIRBY-BAUER TECHNIQUE

    EXP 8 : KIRBY-BAUER TECHNIQUE

    40問 • 2年前
    Quinn Karylle Fuentes

    EXP 9: STAPHYLOCOCCI

    EXP 9: STAPHYLOCOCCI

    Quinn Karylle Fuentes · 29問 · 2年前

    EXP 9: STAPHYLOCOCCI

    EXP 9: STAPHYLOCOCCI

    29問 • 2年前
    Quinn Karylle Fuentes

    Drug incompatibilities.

    Drug incompatibilities.

    Quinn Karylle Fuentes · 41問 · 2年前

    Drug incompatibilities.

    Drug incompatibilities.

    41問 • 2年前
    Quinn Karylle Fuentes

    Drug compatibilities.

    Drug compatibilities.

    Quinn Karylle Fuentes · 41問 · 2年前

    Drug compatibilities.

    Drug compatibilities.

    41問 • 2年前
    Quinn Karylle Fuentes

    BACTERIOLOGY 3

    BACTERIOLOGY 3

    Quinn Karylle Fuentes · 35問 · 2年前

    BACTERIOLOGY 3

    BACTERIOLOGY 3

    35問 • 2年前
    Quinn Karylle Fuentes

    BACTERIOLOGY 3

    BACTERIOLOGY 3

    Quinn Karylle Fuentes · 30問 · 2年前

    BACTERIOLOGY 3

    BACTERIOLOGY 3

    30問 • 2年前
    Quinn Karylle Fuentes

    SUSPENSION.

    SUSPENSION.

    Quinn Karylle Fuentes · 45問 · 2年前

    SUSPENSION.

    SUSPENSION.

    45問 • 2年前
    Quinn Karylle Fuentes

    Colloidal.

    Colloidal.

    Quinn Karylle Fuentes · 40問 · 2年前

    Colloidal.

    Colloidal.

    40問 • 2年前
    Quinn Karylle Fuentes

    BACTERIOLOGY 4 (Rickettsia)

    BACTERIOLOGY 4 (Rickettsia)

    Quinn Karylle Fuentes · 38問 · 2年前

    BACTERIOLOGY 4 (Rickettsia)

    BACTERIOLOGY 4 (Rickettsia)

    38問 • 2年前
    Quinn Karylle Fuentes

    BACTERIOLOGY.

    BACTERIOLOGY.

    Quinn Karylle Fuentes · 44問 · 2年前

    BACTERIOLOGY.

    BACTERIOLOGY.

    44問 • 2年前
    Quinn Karylle Fuentes

    Emulsion.

    Emulsion.

    Quinn Karylle Fuentes · 32問 · 2年前

    Emulsion.

    Emulsion.

    32問 • 2年前
    Quinn Karylle Fuentes

    EMULSION

    EMULSION

    Quinn Karylle Fuentes · 42問 · 2年前

    EMULSION

    EMULSION

    42問 • 2年前
    Quinn Karylle Fuentes

    MEDICAL RELATED PROBLEMS.

    MEDICAL RELATED PROBLEMS.

    Quinn Karylle Fuentes · 36問 · 2年前

    MEDICAL RELATED PROBLEMS.

    MEDICAL RELATED PROBLEMS.

    36問 • 2年前
    Quinn Karylle Fuentes

    MEDICATION RELATED PROBLEMS.

    MEDICATION RELATED PROBLEMS.

    Quinn Karylle Fuentes · 33問 · 2年前

    MEDICATION RELATED PROBLEMS.

    MEDICATION RELATED PROBLEMS.

    33問 • 2年前
    Quinn Karylle Fuentes

    Mycology.

    Mycology.

    Quinn Karylle Fuentes · 30問 · 2年前

    Mycology.

    Mycology.

    30問 • 2年前
    Quinn Karylle Fuentes

    Mycology 2.0

    Mycology 2.0

    Quinn Karylle Fuentes · 34問 · 2年前

    Mycology 2.0

    Mycology 2.0

    34問 • 2年前
    Quinn Karylle Fuentes

    m

    m

    Quinn Karylle Fuentes · 15問 · 2年前

    m

    m

    15問 • 2年前
    Quinn Karylle Fuentes

    ppr

    ppr

    Quinn Karylle Fuentes · 25問 · 2年前

    ppr

    ppr

    25問 • 2年前
    Quinn Karylle Fuentes

    MEDICAL DEVICES.

    MEDICAL DEVICES.

    Quinn Karylle Fuentes · 20問 · 2年前

    MEDICAL DEVICES.

    MEDICAL DEVICES.

    20問 • 2年前
    Quinn Karylle Fuentes

    Pharmacokinetics. (1.0)

    Pharmacokinetics. (1.0)

    Quinn Karylle Fuentes · 86問 · 2年前

    Pharmacokinetics. (1.0)

    Pharmacokinetics. (1.0)

    86問 • 2年前
    Quinn Karylle Fuentes

    Pharmacokinetics (1.1)

    Pharmacokinetics (1.1)

    Quinn Karylle Fuentes · 100問 · 2年前

    Pharmacokinetics (1.1)

    Pharmacokinetics (1.1)

    100問 • 2年前
    Quinn Karylle Fuentes

    Pharmacokinetics (1.2)

    Pharmacokinetics (1.2)

    Quinn Karylle Fuentes · 19問 · 2年前

    Pharmacokinetics (1.2)

    Pharmacokinetics (1.2)

    19問 • 2年前
    Quinn Karylle Fuentes

    Introduction.

    Introduction.

    Quinn Karylle Fuentes · 17問 · 2年前

    Introduction.

    Introduction.

    17問 • 2年前
    Quinn Karylle Fuentes

    Introduction of biochemistry

    Introduction of biochemistry

    Quinn Karylle Fuentes · 76問 · 2年前

    Introduction of biochemistry

    Introduction of biochemistry

    76問 • 2年前
    Quinn Karylle Fuentes

    Intro medicanal chemistry.

    Intro medicanal chemistry.

    Quinn Karylle Fuentes · 56問 · 2年前

    Intro medicanal chemistry.

    Intro medicanal chemistry.

    56問 • 2年前
    Quinn Karylle Fuentes

    Carbohydrates

    Carbohydrates

    Quinn Karylle Fuentes · 75問 · 2年前

    Carbohydrates

    Carbohydrates

    75問 • 2年前
    Quinn Karylle Fuentes

    Carbohydrates 1.1

    Carbohydrates 1.1

    Quinn Karylle Fuentes · 31問 · 2年前

    Carbohydrates 1.1

    Carbohydrates 1.1

    31問 • 2年前
    Quinn Karylle Fuentes

    Detect and quality variation.

    Detect and quality variation.

    Quinn Karylle Fuentes · 56問 · 2年前

    Detect and quality variation.

    Detect and quality variation.

    56問 • 2年前
    Quinn Karylle Fuentes

    INTRODUCTION

    INTRODUCTION

    Quinn Karylle Fuentes · 98問 · 2年前

    INTRODUCTION

    INTRODUCTION

    98問 • 2年前
    Quinn Karylle Fuentes

    lab (1-2)

    lab (1-2)

    Quinn Karylle Fuentes · 15問 · 2年前

    lab (1-2)

    lab (1-2)

    15問 • 2年前
    Quinn Karylle Fuentes

    lab 1-2

    lab 1-2

    Quinn Karylle Fuentes · 14問 · 2年前

    lab 1-2

    lab 1-2

    14問 • 2年前
    Quinn Karylle Fuentes

    Pharmaceutical chemistry.

    Pharmaceutical chemistry.

    Quinn Karylle Fuentes · 45問 · 2年前

    Pharmaceutical chemistry.

    Pharmaceutical chemistry.

    45問 • 2年前
    Quinn Karylle Fuentes

    Pharmaceutical chemistry 1.1

    Pharmaceutical chemistry 1.1

    Quinn Karylle Fuentes · 35問 · 2年前

    Pharmaceutical chemistry 1.1

    Pharmaceutical chemistry 1.1

    35問 • 2年前
    Quinn Karylle Fuentes

    Unit 3.

    Unit 3.

    Quinn Karylle Fuentes · 39問 · 2年前

    Unit 3.

    Unit 3.

    39問 • 2年前
    Quinn Karylle Fuentes

    Histamin and kinins

    Histamin and kinins

    Quinn Karylle Fuentes · 70問 · 2年前

    Histamin and kinins

    Histamin and kinins

    70問 • 2年前
    Quinn Karylle Fuentes

    PUD.

    PUD.

    Quinn Karylle Fuentes · 45問 · 2年前

    PUD.

    PUD.

    45問 • 2年前
    Quinn Karylle Fuentes

    ..

    ..

    Quinn Karylle Fuentes · 61問 · 2年前

    ..

    ..

    61問 • 2年前
    Quinn Karylle Fuentes

    Lipids.

    Lipids.

    Quinn Karylle Fuentes · 67問 · 2年前

    Lipids.

    Lipids.

    67問 • 2年前
    Quinn Karylle Fuentes

    lipids.

    lipids.

    Quinn Karylle Fuentes · 71問 · 2年前

    lipids.

    lipids.

    71問 • 2年前
    Quinn Karylle Fuentes

    LAB ✨

    LAB ✨

    Quinn Karylle Fuentes · 93問 · 2年前

    LAB ✨

    LAB ✨

    93問 • 2年前
    Quinn Karylle Fuentes

    Drug discovery.

    Drug discovery.

    Quinn Karylle Fuentes · 87問 · 2年前

    Drug discovery.

    Drug discovery.

    87問 • 2年前
    Quinn Karylle Fuentes

    disease of lipids.

    disease of lipids.

    Quinn Karylle Fuentes · 13問 · 2年前

    disease of lipids.

    disease of lipids.

    13問 • 2年前
    Quinn Karylle Fuentes

    Intro (identify structure)

    Intro (identify structure)

    Quinn Karylle Fuentes · 57問 · 2年前

    Intro (identify structure)

    Intro (identify structure)

    57問 • 2年前
    Quinn Karylle Fuentes

    Carbohydrates

    Carbohydrates

    Quinn Karylle Fuentes · 98問 · 2年前

    Carbohydrates

    Carbohydrates

    98問 • 2年前
    Quinn Karylle Fuentes

    Dynamic.

    Dynamic.

    Quinn Karylle Fuentes · 96問 · 2年前

    Dynamic.

    Dynamic.

    96問 • 2年前
    Quinn Karylle Fuentes

    Unit 1

    Unit 1

    Quinn Karylle Fuentes · 32問 · 2年前

    Unit 1

    Unit 1

    32問 • 2年前
    Quinn Karylle Fuentes

    問題一覧

  • 1

    Parkinsonism also know as

    Idiopathic Parkinsonism, Primary Parkinsonism, Paralysis Agitans

  • 2

    Critical brain region (part of basal ganglia) for the production of dopamine and has a critical role in modulating motor movement and reward functions as part of the basal ganglia circuitry.

    Substantia Nigra

  • 3

    Slowly progressive degenerative neurological disorder, characterized tremors, muscular rigidity, bradykinesia, and postural and gait abnormalities

    Parkinsonism.

  • 4

    an eosinophilic rounded inclusion which is made up of alpha-synuclein is present in the affected substantia nigra. It appears in dopaminergic neurons before it dies. Aside from PD, it can also be found in other disease like DEMENTIA.

    Lewy body

  • 5

    Sometimes it may have Genetic Predisposition. Mutation in?

    PINK1, Parkin, alpha synuclein genes

  • 6

    its toxicity mainly by promoting the formation of reactive free radicals in the mitochondria of dopaminergic neurons in the substantia nigra. Results to destruction of dopaminergic neurons leading to Parkinson’s disease

    MPP+ exhibits.

  • 7

    Because of inc Ach, most evident at rest and with low-frequency movement.

    Tremor at rest

  • 8

    Muscle stiffness. It can affect any limb, but it's most common in the arms. It can affect one or both arms.

    Muscle rigidity.

  • 9

    Difficulty in initiating movement

    Akinesia

  • 10

    Slowness in performing common voluntary movements

    Bradykinesia

  • 11

    Decrease body movement

    Hypokinesia

  • 12

    Patient walk with a stopped, flexed posture

    Gait & Postural difficulties

  • 13

    The cause is unknown while treatment may be palliative an the disease is incurable. Most patients suffer from this type of parkinsonism

    Primary parkinsonism

  • 14

    ⏤Minimal to no dopamine deficiency ⏤Mild to no improvement to dopaminergic drugs

    Atypical Parkinsonsim

  • 15

    Type of Parkinson’s with a known cause: Disease, Poisoning, Infections or Drug intake

    Secondary parkinsonism

  • 16

    Inhibit the uptake of dopamine in the vesicle. Increasing it’s degradation.

    Reserpine

  • 17

    A rating tool used to gauge the the severity and progression of Parkinson's disease in patients It is used to evaluate the clinical efficacy of antiparkinson’s drugs and to monitor disease progression.

    Unified parkinson's disease scale.

  • 18

    evaluation of mentation, behavior & mood

    Part 1

  • 19

    Unilateral involvement (half of the body) includes major features of tremor, rigidity or bradykinesia, minimal functional impairment

    Stage 1

  • 20

    Bilateral involvement (entire body) Same clinical manifestation to stage 1. Patient don’t have postural abnormalities

    Stage 2

  • 21

    a self-reported evaluation of the activities of daily living (ADL)

    Part 2

  • 22

    is a clinician-scored motor evaluation

    Part 3

  • 23

    the Hoehn and Yahr staging of severity of Parkinson’s disease

    Part 4

  • 24

    The Schwab and England ADL scale.

    Part 5

  • 25

    Mild to moderate bilateral disease Mild postural imbalance, but still able to function independently

    Stage 3

  • 26

    Bilateral involvement with postural abnormalities Patient requires substantial assistance

    Stage 4

  • 27

    Severe disease Patient is restricted to bed or wheelchair unless aided.

    Stage 5

  • 28

    Dopamine precursor

    Levodopa

  • 29

    Drug of choice for Parkinsonism (not always used) ⏤ Most effective drug however prolonged use decreases its efficacy and increase adverse effects

    Levodopa

  • 30

    L-dopa is converted to Dopamine by dopa decarboxylase thereby increasing the CNS levels of Dopamine in the brain. (T/F)

    True

  • 31

    inhibit metabolism of L-dopa in the periphery thereby increase level of DA in the CNS

    Carbidopa

  • 32

    DRUG HOLIDAYS discontinuance of the drug for 3–21 days temporarily improve responsivenes

    Levodopa

  • 33

    more dopa is available for entry into the brain - Reduce the daily requirements of levodopa by approximately 75%

    Carbidopa

  • 34

    What are drugs that may May increase efficacy of levodopa

    Amantadine, benztropine, procyclidine, trihexyphenidyl

  • 35

    increase peripheral breakdown of L-dopa

    Vitamin B6 pyridoxine

  • 36

    What are the ergot derivatives

    Bromocriptine (Parlodel, Provasyn), Pergolide (Permax)

  • 37

    NON ERGOT DERIVATIVES

    Apomorphine (Apokyn), Ropinirole (Requip), Pramipexole (Sifrol)

  • 38

    Dopamine 2 agonist

    BROMOCRIPTINE, ROTIGOTINE, ROPINIROLE

  • 39

    Stimulates both D1 and D2 receptors

    PERGOLIDE

  • 40

    preferential affinity for the D3 receptors

    PRAMIPEXOLE

  • 41

    Also used in hyperprolactinemia but may increase risk of pulmonary fibrosis

    Bromocriptine (Parlodel)

  • 42

    More effective than bromocriptine Also not used because it is associated with VHD (Valvular heart disease)

    Pergolide (Permax)

  • 43

    Reduces symptoms of parkinsonism- smooths out fluctuations in levodopa response effective in on-off phenomenon

    Pramipexole (Sifrol)

  • 44

    Monotherapy in px with mild dse and as a means of smoothing the response to L-dopa

    Monotherapy in px with mild dse and as a means of smoothing the response to L-dopa

  • 45

    An opioid derivative

    Apomorphine (Apokyn)

  • 46

    First dose phenomenon

    Bromocriptine

  • 47

    Cardiac valvulopathy

    Pergolide

  • 48

    Inhibitors of Dopamine Metabolism

    Mao inhibitors, COMT inhibitors

  • 49

    More potent (5x) than selegiline in preventing MPTP induced parkinsonism

    Rasagiline

  • 50

    Retards the breakdown of dopamine Enhances and prolongs the antiparkinson’s effect of levodopa

    Selegiline

  • 51

    Hepatic necrosis is associated with

    Tolcapone

  • 52

    Rapid withdrawal causes hyperpyrexia and confusion

    Entacapone

  • 53

    Prolong the action of levodopa by diminishing its peripheral metabolism Improves duration of “on-time” and dec “off-time”

    Entacapone, Tolcapone

  • 54

    Dopamine Releaser

    Amantadine symmetrel

  • 55

    It has been reported to antagonize the effects of adenosine at adenosine A2A receptors, which are receptors that may inhibit D2 receptor function.

    Amantadine (Symmetrel)

  • 56

    A violaceous mottling of the skin with a "fishnet" reticular appearance.

    Livedo reticularis

  • 57

    Blocks the excitatory neurotransmitter cholinergic influence in the basal ganglia

    Anti muscarinic

  • 58

    What drug is used in Tremor & Rigidity Management

    Anti muscarinic

  • 59

    Normal phenomenon, enhanced amplitude by anxiety, fatigue, thyrotoxicosis, IV Epinephrine

    PHYSIOLOGIC POSTURAL TREMOR

  • 60

    A postural tremor, sometimes familial

    Essential tremor

  • 61

    Present during movement

    Intentional tremor

  • 62

    Due to parkinsonism

    Rest tremor

  • 63

    Consist of rhythmic oscillatory movements around a join

    Tremor

  • 64

    What are the drug odf choice in movement disorder

    B-blockers, Metoprolol, Antiepileptic

  • 65

    Inherited disorder characterized by progressive chorea and dementia that begins at adulthood ⏤Related to imbalance of Dopamine, Ach, GABA, and perhaps other neurotransmitter in the basal ganglia

    Huntington’s Disease

  • 66

    What isnthe drug of choice in Huntington’s Disease

    Tetrabenazine, Reserpine

  • 67

    a condition of the nervous system. TS causes people to have “tics”.

    Tourette Syndrome (TS)

  • 68

    What is the drug of choice in Tourette Syndrome (TS)

    Haloperidol, Pimozide

  • 69

    ⏤Uncontrollable urge to move the legs, usually because of an uncomfortable sensation.

    Restless legs Syndrome

  • 70

    Restless legs syndrome what is the drug of choice

    Dopaminergic, Ropinirole, Opioid analgesics and BZD

  • 71

    Inherited disorder of copper metabolism results in deposition of copper salts in the liver and other tissues

    Wilson’s Disease

  • 72

    Wilson’s Disease in brain

    Uncontrollable movement

  • 73

    Wilson’s Disease in eye

    Kayser-Fleischer rings)

  • 74

    Wilson’s Disease in liver

    Jaundice

  • 75

    Drug of choice in Wilson’s Disease

    Chelating agent, Penicillamine